RPS27P21: A Promising Drug Target / Biomarker (G100131905)

Target Name: RPS27P21

NCBI ID: G100131905

RPS27P21

Other Name(s): ribosomal protein S27 pseudogene 21 | RPS27_9_1229 | Ribosomal protein S27 pseudogene 21

RPS27P21: A Promising Drug Target / Biomarker

The protein RPS27P21 is a key regulator of the actinin-associated protein (AAP) complex, which is involved in a variety of cellular processes, including cytoskeletal organization, cell division, and intracellular transport. The RPS27P21 gene has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Disease-related functions of RPS27P21

RPS27P21 is involved in the regulation of the actinin-associated protein (AAP) complex, which is a protein that helps maintain the cytoskeleton in the cell. The AAP complex is composed of several different proteins, including RPS27, which is the key regulator. This complex plays a crucial role in the proper functioning of the cell, and dysregulation of the AAP complex has been implicated in the development and progression of a wide range of diseases.

One of the key functions of RPS27P21 is its role in the regulation of the cytoskeleton. The cytoskeleton is the structure that gives shape to the cell, and it is involved in many cellular processes, including cell division, intracellular transport, and the regulation of ion channels. RPS27P21 helps to maintain the cytoskeleton by regulating the activity of the microtubules, which are the fundamental structure of the cytoskeleton.

In addition to its role in cytoskeletal regulation, RPS27P21 is also involved in the regulation of cell division. It helps to control the entry of new genetic material into the cell, which is critical for the proper functioning of the cell and the development of the disease.

Another function of RPS27P21 is its role in the regulation of intracellular transport. The intracellular transport system is responsible for moving nutrients, oxygen, and other substances from the cell surface to the cell interior. RPS27P21 helps to regulate this system by controlling the movement of the AAP complex along the microtubules.

Drug targeting and biomarker potential

The potential drug targeting of RPS27P21 is based on its role in the regulation of the AAP complex. Drugs that target this complex have the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the main advantages of targeting RPS27P21 is its potential to treat cancer. The AAP complex plays a crucial role in the regulation of cell division and the proper functioning of the cancer cell, and drugs that target this complex have the potential to inhibit its activity and inhibit the growth of cancer cells. This is an important potential drug target for cancer treatment.

Another potential drug target for RPS27P21 is its role in the regulation of neurodegenerative diseases. The AAP complex is involved in the regulation of the formation and maintenance of the neurotransmitter acetylcholine, which is critical for the proper functioning of the nervous system. Drugs that target this complex, including RPS27P21, have the potential to treat a wide range of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its potential as a drug target, RPS27P21 also has potential as a biomarker. The AAP complex is involved in many cellular processes, including cell division, intracellular transport, and the regulation of ion channels. This makes it a potential source of biomarkers for a wide range of diseases. For example, RPS27P21 has been used as a biomarker for a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and

Protein Name: Ribosomal Protein S27 Pseudogene 21

The "RPS27P21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS27P21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets